Literature DB >> 4157349

Effect of erythromycin analogues on binding of [14C]erythromycin to Escherichia coli ribosomes.

S Pestka, R A Lemahieu.   

Abstract

The relative ability of 44 erythromycin analogues to bind to ribosomes was determined by their effect on [(14)C]erythromycin binding to Escherichia coli ribosomes. The association and dissociation constants of each of these erythromycin derivatives were determined as well as their interaction coefficient for their binding to ribosomes. Substitutions were made on various portions of the erythromycin molecule with retention of substantial activity as measured by inhibition of [(14)C]erythromycin binding to ribosomes. Since the effect of erythromycin analogues on [(14)C]erythromycin binding to ribosomes provides a relatively sensitive assay for these compounds, erythromycin analogues with relatively little affinity for ribosomes could be detected. Compounds with association constants of 10(4) M(-1) were detectable; the association constant for erythromycin binding to ribosomes was approximately 10(8) M(-1). Thus, compounds with 0.0001 the association constant of erythromycin were detectable. This assay could be used alone or in conjunction with microbiological assays for primary screening of active analogues or other compounds which interfere with [(14)C]erythromycin binding to ribosomes. It permits an estimate of the general activity of compounds rapidly and directly. Variables such as metabolic modifications of the compounds and permeability are excluded. The present assay reflects the ability of the compounds to interact directly with their target organelle and may serve as a useful adjunct in developing new compounds.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4157349      PMCID: PMC444675          DOI: 10.1128/AAC.6.4.479

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

1.  Studies on the formation of transfer ribonucleic acid-ribosome complexes. XXIV. Effects of antibiotics on binding of aminoacyl-oligonucleotides to ribosomes.

Authors:  R Harris; S Pestka
Journal:  J Biol Chem       Date:  1973-02-25       Impact factor: 5.157

2.  Studies on the formation of transfer ribonucleic acid-ribosome complexes. 3. The formation of peptide bonds by ribosomes in the absence of supernatant enzymes.

Authors:  S Pestka
Journal:  J Biol Chem       Date:  1968-05-25       Impact factor: 5.157

3.  Chemical modifications of erythromycin antibiotics. I. 3'-de(dimethylamino)erythromycin A and B.

Authors:  P H Jones; E K Rowley
Journal:  J Org Chem       Date:  1968-02       Impact factor: 4.354

4.  Erythromycylamine.

Authors:  E H Massey; B Kitchell; L D Martin; K Gerzon; H W Murphy
Journal:  Tetrahedron Lett       Date:  1970-01       Impact factor: 2.415

5.  The intermolecular complex of erythromycin and ribosome.

Authors:  J C Mao; M Putterman
Journal:  J Mol Biol       Date:  1969-09-14       Impact factor: 5.469

6.  Acid degradation of erythromycin A and erythromycin B.

Authors:  P Kurath; P H Jones; R S Egan; T J Perun
Journal:  Experientia       Date:  1971-04-15

7.  Correlation of effects of erythromycin analogues on intact bacteria and on [14C]erythromycin binding to Escherichia coli ribosomes.

Authors:  S Pestka; R Lemahieu; P Miller
Journal:  Antimicrob Agents Chemother       Date:  1974-10       Impact factor: 5.191

8.  Binding of [14C]erythromycin to Escherichia coli ribosomes.

Authors:  S Pestka
Journal:  Antimicrob Agents Chemother       Date:  1974-10       Impact factor: 5.191

  9 in total
  10 in total

1.  Effect of leucomycins and analogues on binding [14C ]erythromycin to Escherichia coli ribosomes.

Authors:  S Pestka; A Nakagawa; S Omura
Journal:  Antimicrob Agents Chemother       Date:  1974-11       Impact factor: 5.191

2.  Induction of erythromycin resistance in Staphyloccus aureus by erythromycin derivatives.

Authors:  S Pestka; R Vince; R LeMahieu; F Weiss; L Fern; J Unowsky
Journal:  Antimicrob Agents Chemother       Date:  1976-01       Impact factor: 5.191

3.  Binding site of the bridged macrolides in the Escherichia coli ribosome.

Authors:  Liqun Xiong; Yakov Korkhin; Alexander S Mankin
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

4.  Fluorescent assay for estimating the binding of erythromycin derivatives to ribosomes.

Authors:  P Brandt-Rauf; R Vince; R LeMahieu; S Pestka
Journal:  Antimicrob Agents Chemother       Date:  1978-07       Impact factor: 5.191

5.  Correlation of effects of erythromycin analogues on intact bacteria and on [14C]erythromycin binding to Escherichia coli ribosomes.

Authors:  S Pestka; R Lemahieu; P Miller
Journal:  Antimicrob Agents Chemother       Date:  1974-10       Impact factor: 5.191

6.  Single-cell RNA profiling identifies diverse cellular responses to EWSR1/FLI1 downregulation in Ewing sarcoma cells.

Authors:  Roxane Khoogar; Fuyang Li; Yidong Chen; Myron Ignatius; Elizabeth R Lawlor; Katsumi Kitagawa; Tim H-M Huang; Doris A Phelps; Peter J Houghton
Journal:  Cell Oncol (Dordr)       Date:  2022-01-07       Impact factor: 6.730

7.  Synthesis and biological activities of 4"-deoxy-4"-sulfonamido-oleandomycin derivatives.

Authors:  G M Bright; A R English; A A Nagel; J A Retsema; F C Sciavolino
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

Review 8.  The Microenvironment of Tongue Cancer.

Authors:  Want Tao; Zeng Li-Juan; Li Kan; Li Jing-Yuan; Liu Xiang-Qi; Liang Yu-Jie
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

9.  Binding of N-substituted erythromycyclamines to ribosomes.

Authors:  R Vince; D Weiss; S Pestka
Journal:  Antimicrob Agents Chemother       Date:  1976-01       Impact factor: 5.191

10.  Structure of Erm-modified 70S ribosome reveals the mechanism of macrolide resistance.

Authors:  Maxim S Svetlov; Egor A Syroegin; Elena V Aleksandrova; Gemma C Atkinson; Steven T Gregory; Alexander S Mankin; Yury S Polikanov
Journal:  Nat Chem Biol       Date:  2021-01-18       Impact factor: 15.040

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.